Detalhe da pesquisa
1.
Preclinical Bioavailability Strategy for Decisions on Clinical Drug Formulation Development: An In Depth Analysis.
Mol Pharm
; 15(7): 2633-2645, 2018 07 02.
Artigo
Inglês
| MEDLINE | ID: mdl-29799758
2.
Assessment of swallowability and acceptability of scored darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) fixed-dose combination (FDC) tablets in HIV-1-infected children aged ≥6 to <12 years, using matching placebo tablets: A randomized study.
Antivir Ther
; 29(2): 13596535241248282, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38725258
3.
Bioequivalence of a Pediatric Fixed-Dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Compared With Coadministration of the Separate Agents in Healthy Adults: An Open-Label, Randomized, Replicate Crossover Study.
Clin Pharmacol Drug Dev
; 12(11): 1060-1068, 2023 11.
Artigo
Inglês
| MEDLINE | ID: mdl-37335552
4.
In Vitro Evaluation of Poly(lactide-co-glycolide) In Situ Forming Gels for Bedaquiline Fumarate Salt and Pharmacokinetics Following Subcutaneous Injection in Rats.
Pharmaceutics
; 13(8)2021 Aug 10.
Artigo
Inglês
| MEDLINE | ID: mdl-34452192
5.
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
J Psychopharmacol
; 32(12): 1341-1350, 2018 12.
Artigo
Inglês
| MEDLINE | ID: mdl-30260294